Ocugen, Inc. – NASDAQ:OCGN

Add to watchlist

+0.15

+18.28%

Market open

Closed in about 5 hours

-55.00%

month

-55.00%

quarter

+56.67%

year

Market Cap	217.61M
Enterprise value	106.40M

P/E	-2.02
EV/Sales	N/A
EV/EBITDA	-1.31
Price/Sales	N/A
Price/Book	2.11
PEG ratio	0.07
EPS	-0.23

Revenue	N/A
EBITDA	-59.46M
Income	-58.50M
Revenue Q/Q	128.89%
Revenue Y/Y	140.53%

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Ocugen, Inc. (NASDAQ:OCGN): Profit margin
Jun 2023	0	-22.92M
Sep 2023	0	-14.16M
Dec 2023	6.03M	-9.49M	-157.27%
Mar 2024	1.01M	-11.92M	-1175.94%

Ocugen Financials Estimate

Q Y

Ocugen, Inc. (NASDAQ:OCGN): Analyst Estimates
Dec 2023	6.03M	-9.49M	-157.27%
Mar 2024	1.01M	-11.92M	-1175.94%
Sep 2025	1.01M	-20.57M	-2029.45%
Dec 2025	1.01M	-21.86M	-2156.29%

Analysts Price target
Financials & Ratios estimates

Ocugen, Inc. (NASDAQ:OCGN): Debt to assets
Jun 2023	88976000	18.69M	21.01%
Sep 2023	74687000	16.29M	21.81%
Dec 2023	64547000	23.98M	37.16%
Mar 2024	51794000	21.53M	41.57%

Ocugen, Inc. (NASDAQ:OCGN): Cash Flow
Jun 2023	-18.80M	5.72M	15.40M
Sep 2023	-13.70M	-3.36M	-35K
Dec 2023	-11.30M	-2.72M	16K
Mar 2024	-10.59M	-2.35M	-145K

Ocugen alternative data

Social Media

🎓 Academy: How impactful can social media data be in investment decisions

Ocugen, Inc. (NASDAQ:OCGN): Employee count
Aug 2023	84
Sep 2023	84
Oct 2023	84
Nov 2023	84
Dec 2023	84
Jan 2024	84
Feb 2024	84
Mar 2024	84
Apr 2024	84
May 2024	65
Jun 2024	65
Jul 2024	65

Ocugen
Hedge Funds Holdings Q1 2023

13.64% -27.89%

of OCGN is owned by hedge funds

63 -47

hedge funds hold OCGN stock

29.26M -60.67M

shares is hold by hedge funds

OCGN hedge funds holdings changes

Ocugen, Inc. (NASDAQ:OCGN): Insider trades (number of shares)
Period	Buy	Sel
Nov 2024	35000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	26 Nov 2024	FERNANDES PRABHAVATHI director director	Common Stock	10,000	$0.91	$9,100
Purchase	22 Nov 2024	CASTILLO KIRSTEN director director	Common Stock	25,000	$0.91	$22,850
Purchase	14 Jun 2023	ZHANG JUNGE director director	Common Stock	200,278	$0.5	$99,939
Option	16 Feb 2023	MUSUNURI SHANKAR director, officer: Chief Executive Officer director, officer: Chief Execut..	Option (Right to Buy)	100,000	$0.33	$33,000
Sale	16 Feb 2023	MUSUNURI SHANKAR director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	100,000	$1.08	$108,000
Option	16 Feb 2023	MUSUNURI SHANKAR director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	100,000	$0.33	$33,000
Option	17 Jan 2023	MUSUNURI SHANKAR director, officer: Chief Executive Officer director, officer: Chief Execut..	Option (Right to Buy)	100,000	$0.51	$51,000
Sale	17 Jan 2023	MUSUNURI SHANKAR director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	100,000	$1.28	$128,000
Option	17 Jan 2023	MUSUNURI SHANKAR director, officer: Chief Executive Officer director, officer: Chief Execut..	Common Stock	100,000	$0.51	$51,000
Option	16 Dec 2022	MUSUNURI SHANKAR director, officer: Chief Executive Officer director, officer: Chief Execut..	Option (Right to Buy)	95,809	$0.51	$48,863

Status	Patent	Filling date	Issue date
Application	Application ADENO-ASSOCIATED VIRUS VECTOR MEDIATED GENE THERAPY FOR OPHTHALMIC DISEASES Filling date: 26 Oct 2020 Issue date: 29 Apr 2021	26 Oct 2020	29 Apr 2021
Grant	Grant Utility: Preservative free ocular compositions and methods for using the same for treating dry eye disease and other eye disorders Filling date: 30 Jan 2018 Issue date: 25 Aug 2020	30 Jan 2018	25 Aug 2020
Grant	Grant Utility: Ophthalmic compositions and methods of use Filling date: 5 Apr 2018 Issue date: 11 Feb 2020	5 Apr 2018	11 Feb 2020

Ocugen
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 14 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 2 Apr 2024	Q4 2023 Earnings Call Transcript
Q3 2023 9 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 22 Aug 2023	Q2 2023 Earnings Call Transcript

OCGN earnings call transcripts

Ocugen
Executives

Insider	Age	Compensation
Dr. Shankar Musunuri M.B.A., MBA, Ph.D. (1964) Co-Founder, Chairman & Chief Executive Officer	61	$780,670
Mr. Sanjay S. Subramanian M.B.A. (1976) Chief Accounting Officer, Chief Financial Officer, Treasurer, Head of Corporation Devel. & Corporation Sec.	49	$511,150
Dr. Uday B. Kompella Ph.D. (1967) Co-founder & Independent Director	58	$44,770

Ocugen
Latest News

Monday, 23 December 2024
10:40	5 Biotech Breakthrough Stocks to Watch in 2025	zacks.com
Thursday, 19 December 2024
06:38	Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	globenewswire.com
Wednesday, 11 December 2024
07:02	Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit	globenewswire.com
Wednesday, 27 November 2024
07:09	Ocugen CEO to Present at NobleCon20 – Noble Capital Markets' 20th Annual Emerging Growth Equity Conference	globenewswire.com
Wednesday, 20 November 2024
07:30	Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease	globenewswire.com
Tuesday, 19 November 2024
07:02	Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration	globenewswire.com
Thursday, 14 November 2024
17:40	Ocugen (OCGN) Reports Q3 Loss, Misses Revenue Estimates	zacks.com
Friday, 8 November 2024
10:18	Ocugen, Inc. (OCGN) Q3 2024 Earnings Call Transcript	seekingalpha.com
06:45	Ocugen Provides Business Update with Third Quarter 2024 Financial Results	globenewswire.com
Thursday, 7 November 2024
06:30	Ocugen Secures $30 Million in Debt Funding	globenewswire.com
Monday, 28 October 2024
06:30	Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024	globenewswire.com
Tuesday, 22 October 2024
07:02	Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease	globenewswire.com
Thursday, 17 October 2024
07:30	Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results	globenewswire.com
Wednesday, 9 October 2024
06:30	Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial	globenewswire.com
Wednesday, 2 October 2024
06:30	Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa	globenewswire.com
Tuesday, 24 September 2024
07:30	Ocugen to Participate in a Fireside Chat at Chardan's 8th Annual Genetic Medicines Conference	globenewswire.com
Tuesday, 17 September 2024
02:25	Ocugen Extends Cash Runway As OCU400 Nears Key Milestones In Phase 3	seekingalpha.com
Monday, 9 September 2024
06:30	Ocugen Chairman, CEO & Co-founder, Dr. Shankar Musunuri, to Speak During U.S.-India Initiative on Critical and Emerging Technology Workshop	globenewswire.com
Thursday, 5 September 2024
07:00	Ocugen CSO to Participate in 5th Annual Gene Therapy for Ophthalmic Disorders Summit	globenewswire.com
Tuesday, 3 September 2024
07:30	Ocugen to Participate in a Fireside Chat at the H.C. Wainwright 26th Annual Global Investment Conference	globenewswire.com
Wednesday, 28 August 2024
06:30	Ocugen Announces Completion of Dosing in Subjects with Stargardt Disease in High Dose Cohort of Phase 1/2 GARDian Clinical Trial of OCU410ST—A Modifier Gene Therapy	globenewswire.com
Tuesday, 27 August 2024
12:45	Ocugen to Begin Phase III Study on Eye Drug in Canada, Stock Up	zacks.com
Monday, 26 August 2024
07:02	Ocugen, Inc. Announces Health Canada Approval to Initiate Phase 3 Clinical Trial for OCU400 – Modifier Gene Therapy for Broad Retinitis Pigmentosa Indication	globenewswire.com
Tuesday, 20 August 2024
09:00	Ocugen, Inc. Investor Alert (NASDAQ: OCGN): Schubert Jonckheer & Kolbe LLP Investigating Potential Claims Against the Company's Officers and Directors Following Earnings Restatement and Possible Insider Trading	prnewswire.com
Thursday, 8 August 2024
06:45	Ocugen Provides Business Update with Second Quarter 2024 Financial Results	globenewswire.com
Monday, 5 August 2024
06:30	Ocugen, Inc. Announces FDA Approval of Expanded Access Program for Patients with Retinitis Pigmentosa	globenewswire.com
Friday, 2 August 2024
15:22	Ocugen, Inc. Announces Closing of $35 Million Public Offering of Common Stock	globenewswire.com
Wednesday, 31 July 2024
21:15	Ocugen, Inc. Announces Pricing of $35 Million Public Offering of Common Stock	globenewswire.com
16:15	Ocugen, Inc. Announces Proposed Public Offering of Common Stock	globenewswire.com
Monday, 29 July 2024
07:02	Ocugen to Host Conference Call on Thursday, August 8 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2024 Financial Results	globenewswire.com

Ideas & Opinions

Seeking Alpha 18 Jun 2025

Ocugen: Three Potential Gene-Therapy Filings By 2028
Seeking Alpha 1 Jul 2024

Ocugen: Paradigm Shift Gene Therapy Facing Cash Flow Hurdles
Seeking Alpha 19 Apr 2024

Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value
Seeking Alpha 12 Apr 2024

The 'Undercovered' Dozen From March 2024
Seeking Alpha 4 Mar 2023

Stocks To Watch: Jobs Report Drama Could Flip The Script For Investors
Seeking Alpha 25 Jan 2023

Ocugen Will Likely Need Large COVID Studies Going Forward
Seeking Alpha 17 Jan 2023

Ocugen: FDA Sector Head States Bridging Studies Insufficient
Seeking Alpha 28 Sep 2021

Ocugen Stock Forecast: Where Is It Headed After Drop Since May?
Seeking Alpha 8 Jul 2021

Ocugen: Peripheral Scandals Taint This Expired COVID-19 'Me-Too' Longshot
Seeking Alpha 6 Jun 2021

Buy Ocugen For Imminent Catalysts

Frequently Asked Questions (FAQ)

What's the price of Ocugen stock today?

One share of Ocugen stock can currently be purchased for approximately $1.
When is Ocugen's next earnings date?

Unfortunately, Ocugen's (OCGN) next earnings date is currently unknown.
Does Ocugen pay dividends?

No, Ocugen does not pay dividends.
How much money does Ocugen make?

Ocugen has a market capitalization of 217.61M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 142.6% to 6.04M US dollars.
What is Ocugen's stock symbol?

Ocugen, Inc. is traded on the NASDAQ under the ticker symbol "OCGN".
What is Ocugen's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Ocugen?

Shares of Ocugen can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are Ocugen's key executives?
Ocugen's management team includes the following people:
- Dr. Shankar Musunuri M.B.A., MBA, Ph.D. Co-Founder, Chairman & Chief Executive Officer(age: 61, pay: $780,670)
- Mr. Sanjay S. Subramanian M.B.A. Chief Accounting Officer, Chief Financial Officer, Treasurer, Head of Corporation Devel. & Corporation Sec.(age: 49, pay: $511,150)
- Dr. Uday B. Kompella Ph.D. Co-founder & Independent Director(age: 58, pay: $44,770)
Is Ocugen founder-led company?

Yes, Ocugen is a company led by its founders Dr. Shankar Musunuri M.B.A., MBA, Ph.D. and Dr. Uday B. Kompella Ph.D..
How many employees does Ocugen have?

As Jul 2024, Ocugen employs 65 workers, which is 23% less then previous quarter.
When Ocugen went public?

Ocugen, Inc. is publicly traded company for more then 10 years since IPO on 3 Dec 2014.
What is Ocugen's official website?

The official website for Ocugen is ocugen.com.
Where are Ocugen's headquarters?

Ocugen is headquartered at 263 Great Valley Parkway, Malvern, PA.
How can i contact Ocugen?

Ocugen's mailing address is 263 Great Valley Parkway, Malvern, PA and company can be reached via phone at +48 43284701.

Ocugen, Inc.

ocugen.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

+48 43284701

263 Great Valley Parkway
Malvern, PA 19355

CIK: 0001372299
ISIN: US67577C1053
CUSIP: 67577C105